Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

On Thursday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $27.46 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.36. The stock opened at $27.53 and ...

The five-year investment will go toward the construction of a new R&D facility in Beijing to develop innovative therapies and integrate the world’s second most populated country in the company’s ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

The pharmaceutical giant's stock has severely lagged the broader market in 2024, falling 2.43% while the S&P 500 has surged ...

Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend yield ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of developing ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Pfizer has beaten analyst estimate both top- and bottom line. The firm has also raised its full-year guidance. Read my ...